Motor complications in an incident Parkinson's disease cohort

European Journal of Neurology

Volumn 23, Issue 2, 2016, Pages 304-312

  Scott, N W ^a   Macleod, A D ^a   Counsell, C E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Dyskinesias; Levodopa; Motor complications; Motor fluctuations; Parkinson's disease

Indexed keywords

ALCOHOL; CAFFEINE; LEVODOPA; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSKINESIA; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SMOKING; SURVIVAL; TREMOR; UNITED KINGDOM; COMPLICATION; DYSKINESIA, DRUG-INDUCED; INCIDENCE; MIDDLE AGED; SCOTLAND; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SCOTLAND;

EID: 84956590640     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12751     Document Type: Article

References (37)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363: 1783-1794.
2. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-230.
3. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G; Parkinson Study Group. Quality of life in early Parkinson's disease. Mov Disord 2004; 19: 22-28.
4. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
5. Rybicki BA, Johnson CC, Gorell JM. Demographic differences in referral rates to neurologists of patients with suspected Parkinson's disease: implications for case-control study design. Neuroepidemiology 1995; 14: 72-81.
6. Fitzsimmons PR, Blayney S, Mina-Corkill S, Scott GO. Older participants are frequently excluded from Parkinson's disease research. Parkinsonism Relat Disord 2012; 18: 585-589.
7. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011; 82: 1112-1118.
8. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006; 63: 205-209.
9. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005; 20: 342-434.
10. Ku S, Glass GA. Age of Parkinson's disease onset as a predictor for the development of dyskinesia. Mov Disord 2010; 25: 1177-1182.
11. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005; 62: 601-605.
12. Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013; 28: 1064-1071.
13. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial and ropinirole and L-dopa. Mov Disord 2006; 21: 1844-1850.
14. Hassin-Baer S, Molchadski I, Cohen OS, et al. Gender effect on time to levodopa-induced dyskinesias. J Neurol 2011; 258: 2048-2053.
15. Garcia-Ruiz PJ, del Val J, Fernandez IM, Herranz A. What factors influence motor complications in Parkinson disease?: a 10-year prospective study. Clin Neuropharmacol 2012; 35: 1-5.
16. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 2000; 123: 2297-2305.
17. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005; 20(Suppl. 11): S11-S16.
18. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006; 63: 1756-1760.
19. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72: 893-901.
20. Wills AM, Eberly S, Tennis M, et al. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord 2013; 28: 380-383.
21. Mizuno Y, Kondo T, Japanese Istradefylline study group. Adenosine A2a receptor antagonist Istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013; 28: 1138-1141.
22. Taylor KS, Counsell CE, Harris CE, Gordon JC, Smith WC. Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 2006; 21: 976-982.
23. Caslake R, Scott N, Gordon J, et al. Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in north east Scotland: the PINE study. Parkinsonism Relat Disord 2013; 19: 515-521.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
25. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
26. U.S. Department of Agriculture, Agriculture Research Service. USDA National Nutrient Database for Standard Reference, Release 24. 2011.
27. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis, II: Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48: 1503-1510.
28. Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on l-dopa monotherapy. Parkinsonism Relat Disord 2005; 11: 151-155.
29. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomised controlled trial. JAMA 2000; 284: 1931-1938.
30. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66: 563-570.
31. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
32. Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa controlled trials. Eur J Neurol 2014; 21: 433-440.
33. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease. The STRIDE-PD study. Ann Neurol 2010; 68: 18-27.
34. Kipfer S, Stephan MA, Schüpbach WM, Ballinari P, Kaelin-Lang A. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia. Arch Neurol 2011; 68: 1037-1039.
35. Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross IN. Cascade of levodopa dose and weight related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinsonism Relat Disord 2006; 12: 499-505.
36. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008; 15: 493-496.
37. Smith KM, Dahodwala N. Sex differences in Parkinson's disease and other movement disorders. Exp Neurol 2014; 259: 44-56.